drugset / Trial / NCT05915546

The Effect of Food on the Pharmacokinetics (PK) of Emraclidine in Healthy Adult Participants

NCT05915546

Phase 1 Completed 16 enrolled Cerevel Therapeutics, LLC
RandomizedCrossoverOpen-labelTreatment

Summary

The primary purpose of this study is to evaluate the effect of food (a high-fat meal) on the pharmacokinetics of emraclidine and metabolite CV-0000364 following single oral dose administration in healthy adult participants.

Timeline

Start
2023-06-08
Primary completion
2023-07-26
Completion
2023-07-26

Drugs

EvaluationDrugModalityDoseRoute
Subject Emraclidine Small molecule 15 mg Oral

Indications

No indication recorded.